<?xml version="1.0" encoding="UTF-8"?>
<p>Among all referral procedures, 11 concluded with a harmonisation of section 4.3. on contraindications. The majority of the harmonised contraindications were regarding information on hypersensitivity (meropenem, amoxicillin/clavulanic acid, piperacillin/tazobactam, ceftazidime, imipenem/cilastatin, cefuroxime axetil, teicoplanin, ceftriaxone, amoxicillin, fosfomycin). One involved harmonisation of levofloxacin with regards to use during pregnancy and in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency and one concerned oral formulation of fosfomycin in children younger than 12 years. Moreover, two of the 15 referral procedures had a contraindication deleted: for cefuroxime sodium in patients with hepatic dysfunction (lack of evidence) and for colistin/colistimethate sodium-containing products in patients with myasthenia gravis (replacement with a warning in section 4.4). </p>
